全文获取类型
收费全文 | 2760篇 |
免费 | 171篇 |
国内免费 | 6篇 |
专业分类
耳鼻咽喉 | 53篇 |
儿科学 | 196篇 |
妇产科学 | 91篇 |
基础医学 | 240篇 |
口腔科学 | 56篇 |
临床医学 | 171篇 |
内科学 | 641篇 |
皮肤病学 | 52篇 |
神经病学 | 165篇 |
特种医学 | 97篇 |
外科学 | 406篇 |
综合类 | 76篇 |
一般理论 | 1篇 |
预防医学 | 99篇 |
眼科学 | 165篇 |
药学 | 143篇 |
中国医学 | 7篇 |
肿瘤学 | 278篇 |
出版年
2023年 | 21篇 |
2022年 | 25篇 |
2021年 | 95篇 |
2020年 | 41篇 |
2019年 | 75篇 |
2018年 | 105篇 |
2017年 | 71篇 |
2016年 | 75篇 |
2015年 | 68篇 |
2014年 | 126篇 |
2013年 | 119篇 |
2012年 | 210篇 |
2011年 | 219篇 |
2010年 | 110篇 |
2009年 | 94篇 |
2008年 | 140篇 |
2007年 | 137篇 |
2006年 | 128篇 |
2005年 | 104篇 |
2004年 | 77篇 |
2003年 | 94篇 |
2002年 | 93篇 |
2001年 | 62篇 |
2000年 | 73篇 |
1999年 | 71篇 |
1998年 | 20篇 |
1997年 | 14篇 |
1996年 | 16篇 |
1995年 | 15篇 |
1992年 | 33篇 |
1991年 | 43篇 |
1990年 | 32篇 |
1989年 | 28篇 |
1988年 | 18篇 |
1987年 | 22篇 |
1985年 | 19篇 |
1984年 | 11篇 |
1983年 | 16篇 |
1979年 | 12篇 |
1977年 | 14篇 |
1976年 | 16篇 |
1975年 | 12篇 |
1974年 | 10篇 |
1973年 | 13篇 |
1972年 | 16篇 |
1971年 | 12篇 |
1970年 | 11篇 |
1969年 | 11篇 |
1968年 | 15篇 |
1967年 | 12篇 |
排序方式: 共有2937条查询结果,搜索用时 62 毫秒
1.
Apoorva Challa Neeraj Mahajan Seema Sood Arti Kapil Bimal Kumar Das Vishnubhatla Sreenivas Somesh Gupta 《Indian journal of medical microbiology》2022,40(3):433-435
Treatment guidelines for management of uncomplicated gonorrhoeae have been recently modified owing to alarming upsurge in azithromycin resistance. This study investigated the prevalence and genetic determinants of gonococcal azithromycin resistance in India. Four (5.7%) of 70 gonococcal isolates were resistant to azithromycin. Of 16 isolates investigated for molecular mechanisms of resistance, 13 (81.3%) and 6 (37.5%) isolates exhibited mutations in coding and promoter regions of mtrR gene, respectively. However, ermA, ermB and ermC genes or mutations in rrl gene were absent in all isolates. Azithromycin resistance is low in India posing no immediate threat to use of dual-therapy for syndromic management. 相似文献
2.
Harit Kapoor Kush Raj Lohani Tommy H. Lee Devendra K. Agrawal Sumeet K. Mittal 《CTS Clinical and Translational Science》2015,8(6):841-847
Esophageal adenocarcinoma is the fastest rising cancer in the United States. It develops from long‐standing gastroesophageal reflux disease which affects >20% of the general population. It carries a very poor prognosis with 5‐year survival <20%. The disease is known to sequentially progress from reflux esophagitis to a metaplastic precursor, Barrett''s esophagus and then onto dysplasia and esophageal adenocarcinoma. However, only few patients with reflux develop Barrett''s esophagus and only a minority of these turn malignant. The reason for this heterogeneity in clinical progression is unknown. To improve patient management, molecular changes which facilitate disease progression must be identified. Animal models can provide a comprehensive functional and anatomic platform for such a study. Rats and mice have been the most widely studied but disease homology with humans has been questioned. No animal model naturally simulates the inflammation to adenocarcinoma progression as in humans, with all models requiring surgical bypass or destruction of existing antireflux mechanisms. Valuable properties of individual models could be utilized to holistically evaluate disease progression. In this review paper, we critically examined the current animal models of Barrett''s esophagus, their differences and homologies with human disease and how they have shaped our current understanding of Barrett''s carcinogenesis. 相似文献
3.
4.
Guerard W. Byrne Johannes M. Schirmer David N. Fass Sumeet S. Teotia Walter K. Kremers Hui Xu Bashoo Naziruddin Henry D. Tazelaar John S. Logan Christopher G. A. McGregor 《American journal of transplantation》2005,5(5):1011-1020
Microvascular thrombosis is a prominent feature in cardiac delayed xenograft rejection (DXR). We investigated the impact of warfarin or low-molecular-weight heparin (LMWH) anti-coagulation on xenograft function using a heterotopic pig-to-primate model. Donor hearts were from CD46 transgenic pigs and baboon immunosuppression included tacrolimus, sirolimus, anti-CD20 and TPC, an alpha-galactosyl-polyethylene glycol conjugate. Three groups of animals were studied. Group 1 (n = 9) was treated with warfarin, Group 2 (n = 13) with LMWH and Group 3, received no anti-coagulant drugs. The median duration of xenograft function was 20 days (range 3-62 days), 18 days (range 5-109 days) and 15 days (range 4-53 days) in Groups 1 to 3 respectively. Anti-coagulation achieved the targeted international normalized prothrombin ratio (INR) and anti-factor Xa levels consistent with effective in vivo therapy yet, no significant impact on median xenograft function was observed. At rejection, a similar histology of thrombosis and ischemia was apparent in each group and the levels of fibrin deposition and platelet thrombi in rejected tissue was the same. Anti-coagulation with warfarin or LMWH did not have a significant impact on the onset of DXR and microvascular thrombosis. However, a role for specific anti-coagulant strategies to achieve long-term xenograft function cannot be excluded. 相似文献
5.
6.
7.
8.
Ajit Sood Vandana Midha Neena Sood Manu Bansal 《Indian journal of gastroenterology》2006,25(6):283-285
BACKGROUND: The treatment of hepatitis C virus (HCV)-related cirrhosis is difficult due to high frequency of adverse effects. We retrospectively reviewed the case records of patients with HCV cirrhosis to evaluate the efficacy and tolerability of pegylated (peg) interferon and ribavirin treatment in these patients. METHODS: Medical records of 28 patients with HCV-related compensated cirrhosis were reviewed. The treatment protocol was a combination therapy of peg interferon alfa-2b (1 microg/Kg/week) plus oral ribavirin (10-12 mg/Kg/day). Primary endpoint was sustained virological response, with additional endpoints of drug tolerance, clinical or biochemical worsening and death. RESULTS: End-of-treatment virlogic response was seen in 24 of 28 patients (85%) and sustained virologic response in 15 of 28 (53%) patients. Biochemical end-of-treatment response and sustained response were seen in 20 and 16 patients (71% and 57%), respectively. Treatment had to be stopped in 3 patients due to decompensation of liver status in two and drug intolerance in one, while dose modification was required in two patients. CONCLUSIONS: Combination therapy with peg interferon plus ribavirin seems effective in patients with liver cirrhosis. High relapse rate, poor biochemical recovery and possibility of decompensation are issues that need to be kept in mind. 相似文献
9.
10.